The most widely studied therapy involves activating in vivo γδ T cells with zoledronate and/or IL-2, showing positive results in various cancers, including prostate, breast, and melanoma, with Vδ2 T cells expanding at tumor sites. Here, IL2 is linked to neoplasm.